COMPANY
Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development and commercialization of medicinal therapies. From company website Source · checked 2026-10-19
Sources for this description (1)
- Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development and commercialization of medicinal therapies.
- “Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver-, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.” https://smmttx.com/overview/default.aspx (2026-10-19)
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Manager, Global Data Generation | Palo Alto, California, United States | Oct 22, 2026 | Oct 23, 2026 |
| Paralegal | Palo Alto, CA (US) | Oct 21, 2026 | Oct 22, 2026 |
| Director, Regulatory Affairs CMC | Remote | Oct 21, 2026 | Oct 22, 2026 |
| Executive Director, Key Accounts Lead | Remote-Field (US) | Oct 20, 2026 | Oct 21, 2026 |
| Senior Director, Commercial Excellence | Princeton, NJ | Oct 20, 2026 | Oct 21, 2026 |
Timeline
- Trial start Phase 2/Phase 3: A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma source ↗
- Trial start III: Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer source ↗
- Raise Private placement: $500M (total, as published), announced Oct 22, 2025. Source: SEC filing. source ↗
- Trial start Phase 3: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 source ↗
- Trial start Phase 3: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients source ↗
- Trial start III: Phase III Study of AK112 for NSCLC Patients source ↗
- Trial start Phase 3: Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects source ↗
- Trial start Phase 3: Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection source ↗
- Trial start Phase 2: Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) source ↗
- Trial start Phase 1: Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet source ↗
- Trial start Phase 2: A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) source ↗
- Trial start Phase 2: A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) source ↗
- Trial start 1: A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) source ↗
Upcoming milestones
- 2028-04 (ESTIMATED) · Phase 3 · Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 · NCT06767514
- May 31, 2028 (ESTIMATED) · III · Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer · NCT07228832
- Dec 31, 2028 (ESTIMATED) · Phase 3 · Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients · NCT05899608
- Oct 31, 2030 (ESTIMATED) · Phase 2/Phase 3 · A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma · NCT07815665
Funding
- Private placement: $500M (total, as published), announced Oct 22, 2025. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 12
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03595553 | Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection | Phase 3 | Completed | Jan 28, 2019 | Nov 17, 2021 (actual) |
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Active, not recruiting | Oct 26, 2023 | Dec 31, 2028 (estimated) |
| NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | III | Recruiting | Nov 18, 2025 | May 31, 2028 (estimated) |
| NCT06767514 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Recruiting | Feb 27, 2025 | 2028-04 (estimated) |
| NCT07815665 | A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma | Phase 2/Phase 3 | Recruiting | Sep 10, 2026 | Oct 31, 2030 (estimated) |
| NCT06396065 | Phase III Study of AK112 for NSCLC Patients | III | Active, not recruiting | May 4, 2023 | Apr 12, 2025 (actual) |
| NCT04802837 | Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects | Phase 3 | Terminated | May 19, 2021 | Sep 17, 2021 (actual) |
| NCT02858362 | Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) | Phase 2 | Terminated | 2016-06 | Apr 11, 2018 (actual) |
| NCT02784002 | A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) | Phase 2 | Completed | 2014-12 | 2016-08 (actual) |
| NCT02092935 | A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) | Phase 2 | Completed | 2014-04 | 2015-10 (actual) |
| NCT02383511 | Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet | Phase 1 | Completed | 2015-02 | 2015-08 (actual) |
| NCT02056808 | A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) | 1 | Completed | 2013-11 | 2014-05 (actual) |
Open jobs 84
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Senior Manager, Global Data Generation | Palo Alto, California, United States | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Paralegal | Palo Alto, CA (US) | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Director, Regulatory Affairs CMC | Remote | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Executive Director, Key Accounts Lead | Remote-Field (US) | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Director, Commercial Excellence | Princeton, NJ | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Director, National Field Excellence | Remote (US) | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, Site Alliances and Strategy | Remote | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Manager, Quality Assurance | Princeton, NJ | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Director, Market Access Payer Accounts - Northeast | Remote-Field (Northeast US) | Oct 19, 2026 | Oct 21, 2026 | Not stated |
| Oncology Regional Business Director - Mississippi Valley | Arkansas, Louisiana, Mississippi, Tennessee | Oct 19, 2026 | Oct 21, 2026 | Not stated |
| Manager, FP&A | Palo Alto, CA | Oct 19, 2026 | Oct 21, 2026 | Not stated |
| Senior Manager, Analytical Sciences | Princeton, NJ | Oct 19, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, CMC Statistics | Princeton, NJ | Oct 19, 2026 | Oct 21, 2026 | Not stated |
| Clinical Supply Planning Manager | Princeton, NJ | Oct 16, 2026 | Oct 21, 2026 | Not stated |
| Senior Legal Counsel | Princeton, NJ | Oct 16, 2026 | Oct 21, 2026 | Not stated |
| Senior Principal Scientist | Palo Alto, CA (US) | Oct 15, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, Clinical Supply Management (UK/EU) | Oxford, UK, Zug Switzerland, Dublin Ireland | Oct 15, 2026 | Oct 21, 2026 | Not stated |
| Director, Sourcing & Procurement - R&D Clinical Operations and Supplies | Remote (US) | Oct 14, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, Clinical Supply Management | Princeton, NJ (US) and Palo Alto, CA (US) | Oct 14, 2026 | Oct 21, 2026 | Not stated |
| Regional Marketing Director | Princeton, NJ | Oct 14, 2026 | Oct 21, 2026 | Not stated |
| Director, Clinical Scientist | Remote (US) | Oct 14, 2026 | Oct 21, 2026 | Not stated |
| Senior Medical Director | Remote (US) | Oct 14, 2026 | Oct 21, 2026 | Not stated |
| Senior Director, Oncology Clinical Educators | Remote-Field (US) | Oct 13, 2026 | Oct 21, 2026 | Not stated |
| Director, Clinical Operations Analytics & Performance Excellence | Remote | Oct 13, 2026 | Oct 21, 2026 | Not stated |
| Corporate Counsel, Clinical Contracts | Remote (US) | Oct 9, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, Medical Writing | remote | Oct 8, 2026 | Oct 21, 2026 | Not stated |
| Senior Specialist, QA | Ireland, United Kingdom, Switzerland | Oct 8, 2026 | Oct 21, 2026 | Not stated |
| Director, Statistical Programming | Palo Alto, CA (US) | Oct 8, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, Clinical Data Management | Palo Alto, CA | Oct 8, 2026 | Oct 21, 2026 | Not stated |
| Director, Clinical Study Start-Up | Remote | Sep 29, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, Field Sales Training | Princeton, NJ | Sep 29, 2026 | Oct 21, 2026 | Not stated |
| Senior Manager of Technical QA (GMP) | Palo Alto, CA (US) | Sep 21, 2026 | Oct 21, 2026 | Not stated |
| Compliance Manager, Transparency | Princeton, NJ (US) | Sep 19, 2026 | Oct 21, 2026 | Not stated |
| Director, Regulatory Program Management | Remote | Sep 18, 2026 | Oct 21, 2026 | Not stated |
| Associate Director, Pharmacovigilance Operations | Remote | Sep 18, 2026 | Oct 21, 2026 | Not stated |
| Clinical Trial Manager II | Remote | Sep 14, 2026 | Oct 21, 2026 | Not stated |
| Senior Clinical Trial Manager | Remote | Sep 14, 2026 | Oct 21, 2026 | Not stated |
| Senior Director, Regulatory CMC | Remote (US) | Sep 10, 2026 | Oct 21, 2026 | Not stated |
| National Account Director, Government Payers —Medicaid | Remote-Field (US) | Sep 10, 2026 | Oct 21, 2026 | Not stated |
| Sr. Clinical Data Scientist | Palo Alto, CA | Sep 10, 2026 | Oct 21, 2026 | Not stated |
| Sr. Manager, Clinical Quality Assurance | Remote | Sep 9, 2026 | Oct 21, 2026 | Not stated |
| Senior Director, Regional Marketing | Princeton, NJ (US) | Sep 9, 2026 | Oct 21, 2026 | Not stated |
| Senior Manager, Commercial Analytics | Princeton, NJ (US) | Sep 8, 2026 | Oct 21, 2026 | Not stated |
| Chief Commercial Officer | Princeton, NJ (US) | Sep 4, 2026 | Oct 21, 2026 | Not stated |
| Senior Director, Program Management | Palo Alto, California, United States | Sep 4, 2026 | Oct 21, 2026 | Not stated |
| Director, Commercial Analytics & Information | Princeton, NJ | Sep 3, 2026 | Oct 21, 2026 | Not stated |
| IT Business Analyst - G&A | Palo Alto, CA (US) | Aug 31, 2026 | Oct 21, 2026 | Not stated |
| IT Helpdesk Analyst | Palo Alto, CA (US) | Aug 31, 2026 | Oct 21, 2026 | Not stated |
| Regional Medical Science Director (South) | Remote (US) | Aug 27, 2026 | Oct 21, 2026 | Not stated |
| Senior Medical Science Liaison (Northeast) | Remote (US) | Aug 26, 2026 | Oct 21, 2026 | Not stated |